26471
document
[ Rapidity of pain relief , medication requirement and patient satisfaction with reflux treatment in the physician 's office ] . Treatment of gastroesophageal reflux disease ( GERD ) with proton pump inhibitors was investigated in three controlled prospective , randomized open studies . Lansoprazole , omeprazole MUPS and esomeprazole were compared under doctor 's office conditions . The outcomes of interest were the rapidity of pain relief achieved with a single dose , effectiveness and patient satisfaction with on demand therapy . In the first study , 180 patients with chronic and prolonged episodes of reflux were investigated . Time to pain relief following a single dose was 1.1 +/- 0.8 hours with 30 mg lansoprazole , 3.0 +/- 2.5 hours with 20 mgomeprazole MUPS and 2.1 +/- 1.2 hours with 40 mg esomeprazole . Studies 2 and 3 were designed as cross-over studies intended to investigate drug consumption . In study 2 , the amount of lansoprazole consumed was approximately 50 % less than that of omeprazole , and this translated to 81 % patient satisfaction with lansoprazole compared with only 9.5 % for omeprazole . In study 3 comparing lansoprazole and esomeprazole , consumption of the former was 85 % that of the latter . 58 % of the patients opted to continuetreatment with lansoprazole , compared with only 25 % in the case of esomeprazole . The appreciably greater patient satisfaction with lansoprazole was due tothe faster pain relief achieved with this drug .
26472
Intervention_Physical
proton pump inhibitors
26473
Intervention_Pharmacological
Lansoprazole
26474
Intervention_Pharmacological
omeprazole MUPS
26475
Intervention_Pharmacological
esomeprazole
26476
Intervention_Pharmacological
lansoprazole
26477
Intervention_Pharmacological
mgomeprazole
26478
Intervention_Pharmacological
esomeprazole
26479
Intervention_Pharmacological
lansoprazole
26480
Intervention_Pharmacological
omeprazole
26481
Intervention_Pharmacological
lansoprazole
26482
Intervention_Pharmacological
omeprazole
26483
Intervention_Pharmacological
esomeprazole
26484
Intervention_Pharmacological
lansoprazole
26485
Intervention_Pharmacological
esomeprazole
26486
Intervention_Pharmacological
lansoprazole
26487
Outcome_Pain
Rapidity of pain relief
26488
Outcome_Other
medication requirement
26489
Outcome_Other
patient satisfaction
26490
Outcome_Physical
gastroesophageal reflux disease ( GERD )
26491
Outcome_Pain
rapidity of pain relief
26492
Outcome_Other
single dose
26493
Outcome_Other
effectiveness
26494
Outcome_Other
patient satisfaction
26495
Outcome_Pain
pain relief
26496
Outcome_Physical
drug consumption
26497
Outcome_Other
amount of lansoprazole consumed
26498
Outcome_Other
patient satisfaction
26499
Outcome_Other
consumption
26500
Outcome_Other
continuetreatment
26501
Outcome_Other
patient satisfaction
26502
Outcome_Pain
faster pain relief
26503
Participant_Condition
gastroesophageal reflux disease
26504
Participant_Condition
GERD
26505
Participant_Sample-size
180
26506
Participant_Condition
chronic and prolonged episodes of reflux